FDA Approved Indications for this Orphan Drug:Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium.
FDA Marketing Approval issued as of:
Amedra Pharmaceuticals LLC
FDA Designation Date:
FDA Drug Designation:
Treatment of neurocysticercosis due to Taenia solium as: 1) chemotherapy of parenchymal, subarachnoidal and racemose (cysts in spinal fluid) neurocysticercosis in symptomatic cases and 2) prophylaxis of epilepsy and other sequelae in asymptomatic neurocysticercosis.